Insights on clinical trial matching, evidence-informed ranking, and AI in healthcare
Tebentafusp 5-year survival data, conditional TCEs that activate only inside tumors, KRAS resistance paradox, and new trials for kidney cancer, sarcoma, and prostate cancer. How next-generation bispecific molecules are making immunotherapy work in solid tumors.
Read more →CAR-T cells that don't burn out (KIR-CAR), mRNA injections that program your body to make cancer-fighting antibodies (100% response rate), personalized vaccines with 6-year protection, and the first patient treated with in vivo CAR engineering. The next wave of immune-based cancer treatments.
Read more →92 antibody-drug conjugate projects were presented at AACR 2026. The field is moving toward bispecific ADCs targeting two proteins, dual-payload designs carrying two drugs, and novel payloads that overcome resistance. Here's what matters for patients looking for clinical trials.
Read more →Four improvements this month: search results now arrive in 5–15 minutes, non-treatment studies are filtered out more accurately, cross-cancer drug signals inform ranking, and remission status is recognized to prevent irrelevant matches.
Read more →No more blank text boxes. ClinTrialFinder now walks you through clinical trial matching step by step—asking the right questions for your specific disease, showing relevant treatment options and biomarkers, and adapting the number of steps based on your condition. No medical knowledge required.
Read more →You open a trial matching tool and see a text box: "Describe your condition." What do you write? This guide breaks down exactly what information helps—cancer type, stage, prior treatments, biomarkers—and what you can skip.
Read more →Most clinical trial matching tools stop at relevance and eligibility screening. We tested a real cancer patient case and found that TrialGPT-only ranking would have shown the wrong trials first—including a diagnostic imaging study ranked #1. Evidence-informed ranking correctly identified novel therapies as the best options.
Read more →